The stimulator of interferon genes (STING) cellular signaling pathway is a promising target
for cancer immunotherapy. Activation of the intracellular STING protein triggers the …

Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …

Cytokines are soluble proteins that mediate cell-to-cell communication. Based on the
discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal …

Local immunotherapy ideally stimulates immune responses against tumors while avoiding
toxicities associated with systemic administration. Current strategies for tumor-targeted …

Over the past decade, preclinical and clinical research have confirmed the essential role of
interferons for effective host immunological responses to malignant cells. Type I interferons …

The fact that a subset of human cancers showed evidence for a spontaneous adaptive
immune response as reflected by the T cell‐inflamed tumor microenvironment phenotype …

Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this
Review, we discuss accumulating evidence indicating that type I IFNs produced by …

T cell engineering is a powerful means to rapidly generate anti-tumor T cells. The
costimulatory properties of second-generation chimeric antigen receptors (CARs) determine …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumor in adults. Current treatment options typically consist of surgery followed by …

A growing body of evidence suggests that a major subset of patients with advanced solid
tumors shows evidence for a T-cell–inflamed tumor microenvironment. This phenotype has …